Needham Reiterates Buy on Avidity Biosciences, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Avidity Biosciences (NASDAQ:RNA) and maintained a $60 price target.
October 31, 2024 | 9:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating on Avidity Biosciences and maintained a $60 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $60 price target by Needham suggests a positive outlook for Avidity Biosciences. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100